SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 13, 2002
----------------------
COMMISSION FILE NUMBER 1-12584
DELAWARE SHEFFIELD PHARMACEUTICALS, INC. 13-3808303
------------------------------- ------------------------------- ------------------
(State of other jurisdiction of (Exact name of registrant as (I.R.S. Employer
incorporation or organization) specified in its charter) Identification No.)
14528 South Outer Forty Road, Suite 205, St. Louis, Missouri 63017
------------------------------------------------------------ ----------
(Address of principal executive officers) (Zip Code)
Registrant's telephone number, including area code (314) 579-9899
----------------------
Not Applicable
-------------------------------------------------------------
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS
On April 30, 2002, Sheffield Pharmaceuticals, Inc., a Delaware corporation,
issued a press release, a copy of which is attached hereto as Exhibit 99 and is
incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
Exhibit Number Description
-------------- -----------
99 Press Release dated April 30, 2002 issued by Sheffield
Pharmaceuticals, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: May 13, 2002 By: /s/ Scott A. Hoffmann
--------------------------------------
Scott A. Hoffmann
Vice President and Chief Financial Officer